CERo Therapeutics Holdings, Inc. CERO
0.01
0.00
0.00%
as of 25 Sep
- Market cap
- $140.0K
- P/E
- 0.0×
Follow CERO
| Dec '17 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 13.87 | 13.87 | 1.38 | 1.38 | 0.56 | 0.50 | 0.30 |
Net Debt/EBITDA |
— | 3.31 | 3.31 | 14.28 | (0.06) | 0.01 | 0.22 | 0.10 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.53% | 1.53% | 30.33% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.26 | (0.06) | (0.04) | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 2.21 | 2.21 | 1.64 | 1.64 | 0.79 | 1.16 | 0.17 |
Capex/Depreciation |
— | — | — | — | — | 0.00 | 0.00 | 0.46 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 0.00% | (0.39%) | 25.67% | 15.65% | 27.48% | 47.06% | 1,074.49% | |
| — | (0.35%) | (0.18%) | (0.60%) | (1.58%) | (30.70%) | (195.70%) | (1,940.02%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (24.98%) | (24.98%) | (5.75%) | (5.75%) | 1,277.76% | 350.94% | 1,564.16% |
Research and Development Expense of Revenue |
— | — | — | — | — | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | — | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.03) | (303.09) | (0.16) | (474.87) | (19,300.00) | (445.38) | (3.68) |
Cash per Share |
— | 0.05 | 477.65 | 6.23 | 206.91 | 5,337.67 | 114.73 | 0.39 |
Shareholders Equity per Share |
— | 7.43 | (3,334.74) | 0.36 | (4,782.70) | (140,192.33) | (65.33) | (1.29) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Book value per Share |
— | 7.43 | (3,334.74) | 0.36 | (4,782.70) | (140,192.33) | (65.33) | (1.29) |
Free Cash Flow |
— | (0.70) | (0.70) | (1.09) | (1.09) | (5.79) | (12.92) | (15.58) |
Working Capital |
— | 1.26 | 1.26 | 11.62 | 11.62 | (1.54) | (3.69) | (6.35) |
Capital Expenditures |
— | — | — | — | — | — | — | 0.50 |
Net Current Asset Value |
— | (7.89) | (186.39) | 2.47 | (11.00) | (45.21) | (4.39) | (6.35) |
| Other line items | ||||||||
Quick Ratio |
— | 11.20 | 11.20 | 1.37 | 0.02 | 0.46 | 0.45 | 0.18 |
Depreciation/Fixed assets |
— | — | — | — | — | 1.16 | 2.20 | 4.41 |
Cash ROIC |
— | (0.41%) | 10.61% | (2.41%) | 11.06% | 17.37% | (938.53%) | 431.45% |
Accounts Payable Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.03) | (303.09) | (0.16) | (474.87) | (19,300.00) | (445.38) | (3.80) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 |
Average Payables |
— | — | — | — | 0.83 | 1.66 | 3.09 | 6.04 |
Average Assets |
— | 90.04 | 180.08 | 111.22 | 42.37 | 23.75 | 5.67 | 4.92 |
Average Common Equity |
— | — | 81.58 | (2.60) | (4.27) | (26.53) | (23.56) | (8.89) |
Capex to Sales |
— | — | — | — | — | — | — | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates